var data={"title":"Treatment of cat scratch disease","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of cat scratch disease</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/contributors\" class=\"contributor contributor_credentials\">David H Spach, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 01, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cat scratch disease (CSD) is an infectious disease characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/1,2\" class=\"abstract_t\">1,2</a>]. <em>Bartonella</em> <em>henselae</em> is the etiologic agent in most cases of CSD.</p><p>The treatment of CSD will be reviewed here. The microbiology, epidemiology, and clinical features of CSD, <em>Bartonella</em> endocarditis, and other <em>Bartonella</em> infections are discussed separately. (See <a href=\"topic.htm?path=microbiology-epidemiology-clinical-manifestations-and-diagnosis-of-cat-scratch-disease\" class=\"medical medical_review\">&quot;Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease&quot;</a> and <a href=\"topic.htm?path=endocarditis-caused-by-bartonella\" class=\"medical medical_review\">&quot;Endocarditis caused by Bartonella&quot;</a> and <a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-bartonella-quintana-infections\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and treatment of Bartonella quintana infections&quot;</a> and <a href=\"topic.htm?path=south-american-bartonellosis-oroya-fever-and-verruga-peruana\" class=\"medical medical_review\">&quot;South American bartonellosis: Oroya fever and verruga peruana&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL STUDIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with typical cat scratch disease (CSD) have gradual resolution of symptoms, even without specific antibiotic therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/3\" class=\"abstract_t\">3</a>]. In 5 to 14 percent of individuals, the organisms disseminate and infect the liver, spleen, eye, or central nervous system [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Patients with disseminated disease can have life-threatening complications.</p><p>In vitro susceptibility testing often does not correlate with a clinical response and should not be considered in the choice of antibiotics [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/3\" class=\"abstract_t\">3</a>]. The literature on the use of antibiotics in CSD primarily derives from case reports and small series. There is one prospective, randomized trial [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Lymphadenitis studies</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A randomized prospective placebo-controlled trial of 29 immunocompetent patients (including children and adults) with typical cat scratch disease examined the effectiveness of a five-day course of <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (10 <span class=\"nowrap\">mg/kg</span> on day one and 5 <span class=\"nowrap\">mg/kg</span> on the subsequent four days for patients weighing less than 45.5 kg and 500 mg on day 1, followed by 250 mg on the next four days for those weighing at least 45.5 kg) [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/6\" class=\"abstract_t\">6</a>]. Seven of 14 patients who received azithromycin had an 80 percent or more decrease in lymph node volume during a 30-day follow-up period compared with only one of seven placebo recipients. This trial provides the most convincing data in favor of antibiotic treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The largest therapeutic trial was an uncontrolled retrospective study of 268 persons (age range 6 months to 72 years) with CSD [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/7\" class=\"abstract_t\">7</a>]. The mean duration of illness was 14.5 weeks for 66 patients without treatment, 14.5 weeks for 113 patients treated with antibiotics thought to be ineffective, and 2.8 weeks for 89 patients treated with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a>, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, or <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one small nonrandomized series, five adults with CSD and painful lymphadenitis received oral <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> and had rapid clinical improvement without relapse [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another small series, four patients (three children) with localized CSD received therapy with oral <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> for 5 to 10 days, and all had 50 percent reduction in lymph node size by day 5 and complete resolution of lymphadenopathy within 14 days [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Hepatosplenic disease</span></p><p>Hepatosplenic disease in patients with CSD is uncommon as compared with localized disease and is due to systemic dissemination of the organism. Hepatosplenic CSD should not be confused with peliosis hepatis which is caused by either <em>B. henselae</em> or <em>B. quintana</em> and is most often diagnosed in HIV-infected individuals, although other immunocompromised individuals, such as cancer patients and solid organ transplant recipients, have also developed this manifestation.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One report described three patients with CSD who responded to intravenous <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>; two of the patients had extensive hepatic involvement and one had regional lymphadenopathy [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nineteen children (aged 2 to 11) who had hepatosplenic CSD appeared to respond well to <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, either given alone or in combination with either <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/11\" class=\"abstract_t\">11</a>]. These patients most often received rifampin at a dose of 20 <span class=\"nowrap\">mg/kg</span> per day for 14 days.</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Neuroretinitis studies</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective case series of seven consecutive patients with <em>B. henselae</em> neuroretinitis evaluated the outcome of patients treated with <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (100 mg PO twice daily) and <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> (300 mg PO twice daily) for four to six weeks compared with historic controls [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/12\" class=\"abstract_t\">12</a>]. Antibiotic therapy appeared to promote the resolution of retinitis. However, a different report described prompt resolution of <em>B. henselae</em>-associated neuroretinitis in a patient who received no antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/13\" class=\"abstract_t\">13</a>]. Thus, optimal therapy for neuroretinitis remains unknown.</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">ANTIMICROBIAL REGIMENS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the available data, we make the following treatment regimen recommendations according to the clinical disease setting. A Jarisch-Herxheimer reaction can occur after the first several doses of antibiotics [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/14,15\" class=\"abstract_t\">14,15</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Lymphadenitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although some experts would suggest not treating typical cat scratch disease (CSD) in immunocompetent patients with mild to moderate illness [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/3\" class=\"abstract_t\">3</a>], we suggest a five-day course of <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (500 mg on day one, followed by 250 mg for four days for patients weighing more than 45.5 kg; or 10 <span class=\"nowrap\">mg/kg</span> on day one, followed by 5 <span class=\"nowrap\">mg/kg</span> for four days for those weighing less than 45.5 kg [100 lbs]). </p><p>In patients intolerant to <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, we suggest one of the following alternative regimens for a seven- to ten-day course:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">Clarithromycin</a> (15 to 20 <span class=\"nowrap\">mg/kg</span> divided in two doses for those weighing less than 45.5 kg; or 500 mg twice daily for patients weighing more than 45.5 kg)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> (in children, 10 <span class=\"nowrap\">mg/kg</span> every 12 hours, maximum dose 600 mg daily; in adults, 300 mg twice daily)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a> (in children, <a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a> 8 <span class=\"nowrap\">mg/kg</span> per day, sulfamethoxazole 40 <span class=\"nowrap\">mg/kg</span> per day, in two divided doses; in adults, one double strength tablet twice a day)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">Ciprofloxacin</a> (for patients &gt;17 years of age, 500 mg twice a day)</p><p/><p>In addition, needle aspiration of painful suppurative lymph nodes may hasten the relief of symptoms. Although surgical drainage is generally not recommended, excision of the affected lymph nodes may be reasonable in selected patients with infection unresponsive to a prolonged course of treatment. As an example, in one case report, surgical excision was required to achieve resolution of persistent infection in an immunocompromised patient with progressive symptoms, despite receiving approximately nine months of antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Hepatosplenic disease and prolonged fever</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> plus a second agent, such as <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (dosed as above) or <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> (loading dose 2 <span class=\"nowrap\">mg/kg</span> then 1.5 <span class=\"nowrap\">mg/kg</span> every eight hours based upon normal renal function and adjusted with monitoring) for a 10- to 14-day course. The follow-up of patients who are clinically improved is unclear. Some providers believe further testing is not needed in such patients, while others prefer to document that the lesions are regressing by performing an ultrasound six months after treatment.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Neuroretinitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal therapy for neuroretinitis is unknown. Based upon limited data, we would suggest in adults, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (100 mg orally twice daily) plus <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> (300 mg orally twice daily) for four to six weeks in conjunction with close monitoring by an ophthalmologist. For children &le;8 years of age, we suggest a four- to six-week course of rifampin (10 <span class=\"nowrap\">mg/kg</span> every 12 hours, maximum dose 600 mg daily) plus either <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (10 <span class=\"nowrap\">mg/kg</span> on day one, followed by 5 <span class=\"nowrap\">mg/kg</span> for four days for those weighing less than 45.5 kg) or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (<a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a> 8 <span class=\"nowrap\">mg/kg</span> per day, sulfamethoxazole 40 <span class=\"nowrap\">mg/kg</span> per day, in two divided doses).</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Neurologic disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most patients with severe neurologic disease (eg, encephalitis), we administer a combination of <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> plus <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> for 10 to 14 days. In children &le;8 years of age, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (dosed as above) should be substituted for doxycycline. Little is known about the optimal therapy for neurologic manifestations of <em>B. henselae</em> infection. Although either doxycycline or azithromycin can be used [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/17\" class=\"abstract_t\">17</a>], we prefer treatment with doxycycline in adults since there is extensive clinical experience with the use of this agent to treat central nervous system infections caused by other pathogens. </p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Endocarditis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of suspected or proven <em>Bartonella</em> endocarditis is discussed separately. (See <a href=\"topic.htm?path=endocarditis-caused-by-bartonella\" class=\"medical medical_review\">&quot;Endocarditis caused by Bartonella&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H149135197\"><span class=\"h1\">ROLE OF CORTICOSTEROIDS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On rare occasion, we administer steroids to patients with severe or persistent disease. If corticosteroids are used, we start with an initial dose of 1 <span class=\"nowrap\">mg/kg</span> of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (maximum daily dose 80 <span class=\"nowrap\">mg/day)</span> given for 5 to 7 days, with a taper over the subsequent 10 to 14 days. The use of steroids is based upon expert opinion since there are no controlled trials examining their efficacy in patients with cat scratch disease. The rationale for their use is based on the observation that, despite an intense inflammatory response,<strong> </strong>there are very few organisms detected in the lymphoid tissue of patients with classic cat scratch disease or in the granulomatous material of patients with hepatosplenic involvement [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/7,18\" class=\"abstract_t\">7,18</a>]. In addition, multiple case reports have described rapid resolution of localized and systemic symptoms following a course of corticosteroids [<a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/19-21\" class=\"abstract_t\">19-21</a>]. These reports included patients who had progressive <span class=\"nowrap\">and/or</span> persistent disease, despite receiving antimicrobial therapy. Further study is needed to determine if corticosteroids should have a role in the management of cat scratch disease, and if so, what dose would provide optimal benefit. </p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=cat-scratch-disease-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Cat scratch disease (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cat scratch disease (CSD) is an infectious disease usually characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Bartonella</em> <em>henselae</em> is the etiologic agent in most cases of CSD. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with typical CSD have gradual resolution of symptoms, even without specific antibiotic therapy, but in 5 to 14 percent of individuals, the organisms disseminate and infect the liver, spleen, eye, or central nervous system. Patients with disseminated disease can have life-threatening complications. (See <a href=\"#H2\" class=\"local\">'Clinical studies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although some experts would suggest not treating typical CSD in immunocompetent patients with mild to moderate illness, we suggest treatment of all patients with antimicrobial agents (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). The preferred antibiotic for treatment is <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> since this agent is the only one studied in a randomized controlled study. The typical dose is a five-day course (500 mg on day one, followed by 250 mg for four days for patients weighing more than 45.5 kg; or 10 <span class=\"nowrap\">mg/kg</span> on day one, followed by 5 <span class=\"nowrap\">mg/kg</span> for four days for those weighing less than 45.5 kg [100 lbs]). (See <a href=\"#H7\" class=\"local\">'Lymphadenitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other regimens that appear effective in patients with mild to moderate illness who are intolerant to <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> are described above. (See <a href=\"#H7\" class=\"local\">'Lymphadenitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend treatment of patients with hepatosplenic or disseminated disease (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). Acceptable treatment regimens include <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> (in adults, 300 mg twice daily; in children, 10 <span class=\"nowrap\">mg/kg</span> every 12 hours, maximum dose 600 mg daily) plus either <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (dosed as above) or <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> (loading dose 2 <span class=\"nowrap\">mg/kg</span> then 1.5 <span class=\"nowrap\">mg/kg</span> every 8 hours dosed based upon normal renal function and adjusted with monitoring). The usual duration of treatment is 10 to 14 days. (See <a href=\"#H8\" class=\"local\">'Hepatosplenic disease and prolonged fever'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend treatment of all patients with neuroretinitis or neurologic disease (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). An acceptable treatment regimen in adults is <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (100 mg orally twice daily) plus <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> (300 mg orally twice daily). In children &le;8 years of age, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (dosed as above) should substitute for doxycycline. The usual duration of treatment is four to six weeks for neuroretinitis and 10 to 14 days for other neurologic disease. Neuroretinitis should be managed in conjunction with close monitoring by an ophthalmologist. (See <a href=\"#H9\" class=\"local\">'Neuroretinitis'</a> above and <a href=\"#H10\" class=\"local\">'Neurologic disease'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/1\" class=\"nounderline abstract_t\">Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16:163.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/2\" class=\"nounderline abstract_t\">Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12:137.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/3\" class=\"nounderline abstract_t\">Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/4\" class=\"nounderline abstract_t\">Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 1985; 139:1124.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/5\" class=\"nounderline abstract_t\">Margileth AM. Cat scratch disease. Adv Pediatr Infect Dis 1993; 8:1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/6\" class=\"nounderline abstract_t\">Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17:447.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/7\" class=\"nounderline abstract_t\">Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11:474.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/8\" class=\"nounderline abstract_t\">Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA 1991; 265:1563.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/9\" class=\"nounderline abstract_t\">Chia JK, Nakata MM, Lami JL, et al. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 1998; 26:193.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/10\" class=\"nounderline abstract_t\">Bogue CW, Wise JD, Gray GF, Edwards KM. Antibiotic therapy for cat-scratch disease? JAMA 1989; 262:813.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/11\" class=\"nounderline abstract_t\">Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28:778.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/12\" class=\"nounderline abstract_t\">Reed JB, Scales DK, Wong MT, et al. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology 1998; 105:459.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/13\" class=\"nounderline abstract_t\">Rosen BS, Barry CJ, Nicoll AM, Constable IJ. Conservative management of documented neuroretinitis in cat scratch disease associated with Bartonella henselae infection. Aust N Z J Ophthalmol 1999; 27:153.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/14\" class=\"nounderline abstract_t\">Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/15\" class=\"nounderline abstract_t\">Koehler JE, Duncan LM. Case records of the Massachusetts General Hospital. Case 30-2005. A 56-year-old man with fever and axillary lymphadenopathy. N Engl J Med 2005; 353:1387.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/16\" class=\"nounderline abstract_t\">King KY, Hicks MJ, Mazziotti MV, et al. Persistent cat scratch disease requiring surgical excision in a patient with MPGN. Pediatrics 2015; 135:e1514.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/17\" class=\"nounderline abstract_t\">Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/18\" class=\"nounderline abstract_t\">Florin TA, Zaoutis TE, Zaoutis LB. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection. Pediatrics 2008; 121:e1413.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/19\" class=\"nounderline abstract_t\">ECKHARDT WF Jr, LEVINE AI. Corticosteroid therapy of cat-scratch disease. Results of treatment in three cases with rapid resolution of painful lymphadenopathy; Tietze's syndrome and bilateral cervical adenitis as new complications. Arch Intern Med 1962; 109:463.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/20\" class=\"nounderline abstract_t\">Lerdluedeeporn P, Krogstad P, Roberts RL, Stiehm ER. Oral corticosteroids in cat-scratch disease. Clin Pediatr (Phila) 2003; 42:71.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-cat-scratch-disease/abstract/21\" class=\"nounderline abstract_t\">Bryant K, Marshall GS. Hepatosplenic cat scratch disease treated with corticosteroids. Arch Dis Child 2003; 88:345.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5530 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL STUDIES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Lymphadenitis studies</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Hepatosplenic disease</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Neuroretinitis studies</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">ANTIMICROBIAL REGIMENS</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Lymphadenitis</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Hepatosplenic disease and prolonged fever</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Neuroretinitis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Neurologic disease</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Endocarditis</a></li></ul></li><li><a href=\"#H149135197\" id=\"outline-link-H149135197\">ROLE OF CORTICOSTEROIDS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H3834063\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-treatment-of-bartonella-quintana-infections\" class=\"medical medical_review\">Clinical features, diagnosis, and treatment of Bartonella quintana infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endocarditis-caused-by-bartonella\" class=\"medical medical_review\">Endocarditis caused by Bartonella</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-clinical-manifestations-of-bartonella-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microbiology-epidemiology-clinical-manifestations-and-diagnosis-of-cat-scratch-disease\" class=\"medical medical_review\">Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cat-scratch-disease-the-basics\" class=\"medical medical_basics\">Patient education: Cat scratch disease (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=south-american-bartonellosis-oroya-fever-and-verruga-peruana\" class=\"medical medical_review\">South American bartonellosis: Oroya fever and verruga peruana</a></li></ul></div></div>","javascript":null}